Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

OTC OFFICE DRUG REVIEW STAFF PROJECTED TO GAIN FIVE EMPLOYEES in fiscal year 1994 from funds derived from user fees under a staff allocation plan devised by Center for Drug Evaluation and Research management. The allocation of five additional employees would go to the Office of OTC Drug Evaluation's Medical Review Staff, which was formed earlier this year with the appointment of Debra Bowen, MD, as director in order to provide the OTC office with NDA review capabilities. CDER administrators are projecting an expanded OTC review staff in anticipation of the office assuming a greater role in new drug reviews, particularly for Rx-to-OTC switch applications. Under the FDA user fee act passed by Congress in 1992, the agency is directed to use the revenues from drug and biologics user fees for improving review functions and expanding the review staff within the centers. Based on internal planning allocations, the Center for Drug Evaluation and Research is set to gain a total of 121 full-time equivalents during the current fiscal year from user fees. The allocation sets a hiring ceiling for CDER of 161 employees in FY 1994. Speaking at the Nonprescription Drug Manufacturers Association's annual research and scientific conference on Nov. 19, FDA Monograph Review Staff Director William Gilbertson, PharmD, pointed out that "there has been no growth of the [OTC] office in the last year in terms of new additions other than the appointment of [Bowen]." Gilbertson reported that the OTC office currently has a total of 30 professional staff and nine clerical workers and that 21 of the professional staff are devoted to the OTC monograph review. The medical staff will soon double in size with the addition of another medical officer joining Bowen sometime in December, Gilbertson indicated. The appointment is not yet official.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts